Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17374952 | 0.87 | CPS1 (0.55) | CPS1NPC1RAB9A | |
| SCHEMBL28266357 | 0.83 | EGFR (0.47) | MAPT | |
| SCHEMBL2258923 | 0.83 | KDM4E (0.60) | CPS1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29228596 | 0.81 | KDM4E (0.43) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21395373 | 0.81 | NOS2 (0.48) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13387623 | 0.81 | HPGD (0.48) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7941887 | 0.80 | CPS1 (0.46) | CPS1MAPTHTTNPSR1NPC1 | |
| SCHEMBL16355744 | 0.80 | CSNK2A1 (0.38) | CYP1A2CYP2C19MAPTHTTNPC1 | |
| SCHEMBL4688965 | 0.79 | KDM4E (0.45) | CPS1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14505214 | 0.79 | GAA (0.40) | KDM4ECYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071426-A | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | 基因泰克公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | CPS1 2888/4885KDM4E 2650/4885CYP1A2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.